ライフサイエンスコーパス: CCU

1 re inoculated intranasally with a low (10(1) CCU; n = 6), medium (10(3) CCU; n = 6), or high (10(5) C

2 last sense codon of tnaC, proline codon 24 (CCU), is translated by tRNA(2)(Pro).

3 with a low (10(1) CCU; n = 6), medium (10(3) CCU; n = 6), or high (10(5) CCU; n = 5) dose of M. agass

4 fold preference for 5'-CCC substrate over 5'-CCU substrate, which explains why A3G displays almost no

5 ), medium (10(3) CCU; n = 6), or high (10(5) CCU; n = 5) dose of M. agassizii 723 or with sterile SP4

6 m cells, high-inoculum U. urealyticum (10(6) CCU) (i) stimulated TNF-alpha and IL-8, but not IL-6 or

7 hIR mRNA, and deletion mapping implicated a CCU motif 448 nt upstream of the initiator AUG in PTB bi

8 or Met-tRNA, eIF2, or GTP hydrolysis, with a CCU triplet in the ribosomal P site and a GCU triplet in

9 A group I intron interrupts the tRNA(Arg)CCU gene of the alpha-purple bacterium Agrobacterium tum

10 Of 10 newly identified tRNA(Arg)CCU genes, we found only two that contained an intron ho

11 ocystis aeruginosa and alpha-purple tRNA(Arg)CCU introns suggest that these introns share a more rece

12 ac ischemia, in hospitals with high-capacity CCUs and relatively low-capacity cardiac telemetry units

13 lemetry unit at hospitals with high-capacity CCUs or telemetry units.

14 able angina, in hospitals with high-capacity CCUs, use of ACI-TIPI was associated with a reduction in

15 nd 82 females) from different ICUs (cardiac [CCU], cardiac stepdown [CICU], medical [MICU], and surgi

16 ed that MazF-mt3 cleaves RNA at UU CCU or CU CCU and MazF-mt7 at U CGCU ( indicates the cleavage site

17 NA(Pr)(o)3, which allows this tRNA to decode CCU in addition to CCG and CCA, also affects frameshifti

18 Thus, far, emerging CCU technologies have been environmentally assessed with

19 egies to increase the net CO(2) benefit from CCU concrete.

20 sequence of the precursor (G/UCU) becomes G/CCU, resembling a 3'-tRNase anti-determinant.

21 gency room visits (1.1 more visits), and ICU-CCU admissions (0.8 more admissions).

22 sit (OR, 2.00; 95% CI, 1.87 to 2.14), or ICU-CCU admission (OR, 3.89; 95% CI, 3.81 to 3.96) increased

23 visit, or intensive-coronary care unit (ICU-CCU) admission in the 2 days after a missed treatment re

24 ACI-TIPI was associated with a reduction in CCU admissions from 14% to 10%, a change of -32% (CI, -5

25 ACI-TIPI was associated with a reduction in CCU admissions from 15% to 12%, a change of -16% (95% CI

26 ACI-TIPI was associated with a reduction in CCU admissions from 26% to 13%, a change of -50% (CI, -7

27 of CO(2), change in compressive strength in CCU concrete and uncertainty and variability in CCU conc

28 concrete and uncertainty and variability in CCU concrete production processes.

29 revealed that ORF2 begins with a noncognate CCU triplet.

30 o), a tRNA(Pro) that translates CCG, but not CCU.

31 Notably, CCU patients demonstrated an interleukin-6-dependent enh

32 t methods to evaluate the climate benefit of CCU chemicals should additionally account for the change

33 igher likelihood of the net CO(2) benefit of CCU concrete being negative i.e. there is a net increase

34 Finally, in the context of CCU, an outlook is given on recent developments in LCA t

35 to chemical catalysts for the development of CCU strategies since biocatalysis conforms 10 of the 12

36 y important aspects for conducting an LCA of CCU are identified and illustrated with CCU examples.

37 w gives a jargon-free introduction of LCA of CCU directed at LCA novices.

38 To enhance the use of LCA of CCU, this tutorial review gives a jargon-free introducti

39 s as a checklist through all steps in LCA of CCU: from defining the LCA purpose and the system bounda

40 mg of bilastine in reducing the symptoms of CCU and inflammatory mediator release following cold cha

41 te the greatest climate ROI and are the only CCU pathways with a higher likelihood of generating a cl

42 of comorbidities in patients that occupy our CCU beds is continuously growing.

43 ure and utilization for concrete production (CCU concrete) is estimated to sequester 0.1 to 1.4 gigat

44 We analyzed a prospective CCU registry of 12,648 admissions by 9,557 patients over

45 and where these other demands are satisfied, CCU in the chemical industry could efficiently contribut

46 Most large-scale CCU technologies are found to be less efficient in reduc

47 novel motif which consists of the sequence (CCU)(n) as part of a polypyrimidine-rich tract and permi

48 uired to achieve this goal, where successful CCU (Carbon Capture and Utilization) technologies will h

49 dictor of short- and long-term events in the CCU population.

50 No longer is the CCU merely an observation unit for peri-infarction compl

51 er measurements were the bed capacity of the CCU relative to that of the telemetry unit; training or

52 Increased expression of the CCU/CCA/CCG-decoding tRNA(Pr)(o)3 on a multicopy plasmid

53 s result varied as expected according to the CCU and cardiac telemetry unit capacities and physician

54 ot change appropriate admission (96%) to the CCU or telemetry unit at hospitals with high-capacity CC

55 ombination of mutant initiator tRNA with the CCU anticodon and the reporter system developed here pro

56 Complementarity of this CCU triplet with sequences in the IRES is important for

57 ing anticodon sequence mutations from CAU to CCU (the C35 mutant) or to CUA (the U35A36 mutant).

58 ing a unique variant of the single-copy tRNA(CCU)(Arg) gene at its native genomic location.

59 y department triage to a coronary care unit (CCU), telemetry unit, ward, or home.

60 ality in patients in the coronary care unit (CCU).

61 rate (HR) data; and a central control unit (CCU) that updates stimulation protocols based on the acq

62 on admission to either critical care units (CCU) or general wards.

63 roup; n = 10) or 10(8) color-changing units (CCU) (total dose) of M. agassizii 723 (experimental infe

64 ot commonly the case in coronary care units (CCUs) in this country.

65 U. urealyticum (10(3) color-changing units [CCU]) (i) partially blocked the LPS-stimulated IL-6 rele

66 tions and more than 100000 fewer unnecessary CCU admissions.

67 Cold contact urticaria (CCU) is characterized by itchy wheal and flare responses

68 we show that carbon capture and utilization (CCU) has the technical potential to decouple chemical pr

69 Carbon capture and utilization (CCU) is a promising strategy for the production of fuels

70 r, so-called carbon capture and utilization (CCU) options do not inevitably lead to improved environm

71 these three carbon capture and utilization (CCU) pathways to determine the most effective use of cap

72 n integrated carbon capture and utilization (CCU), has rarely been studied.

73 tal benefits of CO2 capture and utilization (CCU), life cycle assessment (LCA) is considered as suita

74 strategy for carbon capture and utilization (CCU).

75 e determined that MazF-mt3 cleaves RNA at UU CCU or CU CCU and MazF-mt7 at U CGCU ( indicates the cle

76 Among 237 records, 140 were CCU admissions (mean age 57, 69% male) and 97 were gener

77 ors, we determine the net CO(2) benefit when CCU concrete produced from CO(2) curing and mixing subst

78 A of CCU are identified and illustrated with CCU examples.

79 Twenty patients with CCU were included in this randomized, crossover, double-

80 ve in reducing the symptoms of patients with CCU.

81 e codon for the C-terminal Pro residue, with CCU and CCC promoting efficient +1 frameshifting.